Category - Developments

Developments

PharmaJet needle free system cleared for first plasmid DNA COVID-19 vaccine

Closely-held PharmaJet announced that its partner, Zydus Cadila, has received Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world’s first plasmid DNA vaccine for...

August 23, 2021

Developments

111, Inc. deepens partnership with Bayer

111, Inc. (NASDAQ:YI) has expanded its existing partnership with Bayer Healthcare in China. The original partnership was signed in September 2020 and involved collaborating on drug commercialization initiatives in China...

August 16, 2021

Developments

Tryp Therapeutics, Calvert Labs in pact to study psilocybin formulations

Tryp Therapeutics (CSE:TRYP; OTCQB:TRYPF) agreed with Calvert Labs, an Altasciences company, to design and execute exploratory studies related to Tryp’s psilocybin-for-neuropsychiatric disorders (PFN) program. The...

August 10, 2021

Developments

Altamira reports protective effects of Bentrio nasal spray against Influenza A virus

Altamira Therapeutics (NASDAQ:CYTO) announced positive outcomes from testing Bentrio for prophylactic or therapeutic use in influenza A virus infection. Bentrio is a drug-free nasal spray being developed by the...

August 6, 2021

Developments

Profound Medical posts sequential 145% jump in Q2 recurring revenue

Profound Medical (NASDAQ:PROF; TSX:PRN) reported a 145% increase in recurring revenue for the second quarter, compared with the first quarter of 2021. Total revenue, including capital sales outside of the U.S...

August 5, 2021

Developments

iBio featured in Genetic Engineering & Biotechnology News

The advantages of iBio’s (NYSE American:IBIO) plant-based drug production system was featured in the Aug. 4 edition of Genetic Engineering & Biotechnology News. The article quoted Randy Maddux, COO of iBio, who...

August 5, 2021

Developments

111, Inc. in strategic pact with Suzhou Zelgen to develop platform for liver cancer patients in China

111, Inc. (NASDAQ: YI) announced a strategic cooperation agreement with Suzhou Zelgen Biopharmaceuticals (688266.SH), an innovative drug R&D and production company. The agreement will allow 111, a leading tech...

August 3, 2021

Developments

CymaBay in $100-million non-dilutive financing for Phase 3 trial

CymaBay Therapeutics (NASDAQ:CBAY) announced a $100-million non-dilutive financing transaction with Abingworth to fund the Phase 3 development program for seladelpar in primary biliary cholangitis (PBC), including the...

August 2, 2021

Developments

Deep Genomics raises $180-million (U.S.) to develop drugs discovered by AI

University of Toronto spinout, Deep Genomics, raised $180-million (U.S.) led by Softbank’s Vision Fund 2 to bankroll its efforts to discover and develop drugs using artificial intelligence. The funding group included...

July 28, 2021

Developments

Talkiatry completes $20-million Series A funding

Closely-held Talkiatry, a provider of accessible in-network psychiatric care, completed its $20-million a Series A funding, of which $15-million was led by Left Lane Capital, with participation from Dr. Richard Park...

July 28, 2021

Category - Developments

General

More